Prosecution Insights
Last updated: April 19, 2026

Examiner: RIGA, MICHAEL ANGELO

Tech Center 1600 • Art Units: 1633 1634

This examiner grants 52% of resolved cases

Performance Statistics

52.0%
Allow Rate
-8.0% vs TC avg
89
Total Applications
+67.3%
Interview Lift
1634
Avg Prosecution Days
Based on 50 resolved cases, 2023–2026

Rejection Statute Breakdown

4.4%
§101 Eligibility
14.4%
§102 Novelty
37.0%
§103 Obviousness
37.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17309403 AAV VIRAL VECTORS AND USES THEREOF Non-Final OA NOVARTIS AG
17430086 MESENCHYMAL STEM CELL SHEET AND USE THEREOF Final Rejection BOE TECHNOLOGY GROUP CO., LTD.
17612669 MODIFIED VIRAL PARTICLES AND USES THEREOF Final Rejection Regeneron Pharmaceuticals, Inc.
18640282 PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS RESISTANT ANIMALS Final Rejection The Curators of the University of Missouri
18546746 Transplantation of Liver Cells by Administration to the Biliary Tree of the Liver Non-Final OA Cambridge Enterprise Limited
17998330 COMPOSITIONS USEFUL IN TREATMENT OF KRABBE DISEASE Final Rejection The Trustees of the University of Pennsylvania
17433195 COMPOSITIONS USEFUL IN TREATMENT OF KRABBE DISEASE Non-Final OA The Trustees of the University of Pennsylvania
18035021 LIVE CELL ASSAY FOR PROTEASE INHIBITION Non-Final OA Regents of the University of Minnesota
17789314 Method for Producing Serum for Culturing Mammalian Cells Non-Final OA NIPRO CORPORATION
17268635 PHARMACEUTICAL COMPOSITION FOR TREATING CARTILAGE DAMAGE, COMPRISING NASAL SEPTUM CHONDROCYTES Non-Final OA THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
17260443 PLURIPOTENT STEM CELL-DERIVED PLATE-SHAPED CARTILAGE AND METHOD FOR PRODUCING THE SAME Final Rejection KYOTO UNIVERSITY
17425709 ANUCLEATE CELL-DERIVED VACCINES Final Rejection STEMCELL TECHNOLOGIES CANADA INC.
17612487 METHODS OF CULTURING QUIESCENT HEMATOPOIETIC STEM CELLS AND TREATMENT METHODS Final Rejection ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
17309207 REGENERATIVE ABSCOPAL EFFECTS Non-Final OA Figene, LLC
17917198 B7-H3 CHIMERIC ANTIGEN RECEPTORS Non-Final OA St. Jude Children's Research Hospital, Inc.
16990185 NON-HLA RESTRICTED T CELL RECEPTORS AND USES THEREOF Non-Final OA MEMORIAL SLOAN-KETTERING CANCER CENTER
18258778 METHOD FOR PRODUCING OLIGODENDROCYTES Non-Final OA Koji TANABE
17434513 RECOMBINANT VECTORS COMPRISING ARYLSULFATASE A AND THEIR USES IN STEM CELL THERAPY FOR THE TREATMENT OF METACHROMATIC LEUKODYSTROPHY Non-Final OA VERSITECH LIMITED
18212404 USE OF PROSTAGLANDIN E2 (PGE2)-PRIMED MESENCHYMAL STEM CELL (MSC) PRODUCT IN PREPARATION OF DRUG FOR TREATING LUNG INJURY (LI) Non-Final OA NANKAI UNIVERSITY
18285180 MEDIUM COMPOSITION FOR CULTURING MUSCLE STEM CELL COMPRISING CURCUMIN LONGA, GLYSIN, OR INSULIN FOR PROLIFERATION OF MUSCLE STEM CELL Non-Final OA DANAGREEN CO., LTD.
17047945 METHOD FOR MONITORING THE VIABILITY OF A GRAFT Non-Final OA HEMARINA
16970216 COMPOSITIONS AND METHODS FOR MEMBRANE PROTEIN DELIVERY Non-Final OA FLAGSHIP PIONEERING INNOVATIONS V, INC.
17628105 METHODS AND COMPOSITIONS FOR ENHANCED EXPANSION AND CYTOTOXICITY OF NATURAL KILLER CELLS Non-Final OA NKARTA, INC.
17997377 METHOD TO PRODUCE T CELLS AND USES THEREOF Non-Final OA OSPEDALE SAN RAFFAELE S.R.L.
17291658 CARBON NANOTUBE COMPOSITE VECTOR HAVING SYNERGISTIC EFFECT OF PHOTOTHERMAL THERAPY AND GENE THERAPY, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Non-Final OA DALIAN MINZU UNIVERSITY
17414425 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEGENERATIVE OCULAR DISEASES Final Rejection Massachusetts Ear and Eye Infirmary
17309030 PROCESS FOR ENGINEERING TARGETED NANOPARTICLES Final Rejection University of North Texas Health Science Center
17050794 TALEN-BASED AND CRISPR/CAS-BASED GENE EDITING FOR BRUTON'S TYROSINE KINASE Non-Final OA Seattie Children's Hospital d/b/a Seattle Children's Research Institute

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month